David Ladkani

Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial

Jerry S. Wolinsky, Ponnada A. Narayana, Paul O’Connor et al. · Annals of Neurology · 2007 · 423 citations · Full text

Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study

Anat Achiron, Uri Givon, David Magalashvili et al. · Multiple Sclerosis Journal · 2014 · 82 citations

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial

Marco Rovaris, Giancarlo Comi, Maria A. Rocca et al. · Multiple Sclerosis Journal · 2007 · 54 citations

Copaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustained

J. S. Wolinsky, Giancarlo Comi, Massimo Filippi et al. · Neurology · 2002 · 50 citations

Neurological Disorder, Neurological Progress, Mri-monitored Disease +18

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing–remitting MS

J. A. Cohen, Marco Rovaris, Andrew Goodman et al. · Neurology · 2007 · 46 citations